Cereno Scientific announced that topline results from the Phase I study with CS014 will be communicated in mid-July 2025. The study evaluates the safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeated doses of CS014 in healthy volunteers. The study was successfully completed in April and is currently in the process of collecting, verifying and analyzing data for report completion. CS014 is an HDAC inhibitor with a multimodal mechanism of action under development for the treatment of idiopathic pulmonary fibrosis (IPF).
|
Published June 30, 2025
Cereno Scientific communicates Phase I results in July
Notes
Johnson & Johnson acquires Halda Therapeutics for $3 billion
Magle Group submits application for EmboCept S
Quia Pharma is delisted from Nasdaq
Stenocare acquires CannGros
Lundbeck enters the fight for Avadel
Klaria's partner CNX starts production of migraine film
Sofinnova Partners raises EUR 650 million in new fund
NEWSLETTER
Today's news roundup
News roundup Monday, November 17
Upcoming events
MedTech Summit 2026
A new, much-needed MedTech forum in one of Europe's leading life science clusters. As the first event of its kind...
Recommended
Pila Pharma stands out in next-generation obesity pipeline
Novo Nordisk challenges Pfizer in billion-dollar battle for Metsera
New major investment will strengthen Europe's life science sector
The pharmaceutical sector is riding a USD 61,6 billion R&D wave
SwedenBIO wants to give growth power to the industry
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account